Insights

Gathering insights about Rhythm…

Similar companies to Rhythm

Rhythm Tech Stack

Rhythm uses 8 technology products and services including Adobe Target, Linkedin Insight Tag, Cloudflare, and more. Explore Rhythm's tech stack below.

Adobe Target
A/B Testing
Linkedin Insight Tag
Analytics
Cloudflare
Content Management System
Shopify
E-commerce
GraphQL
Programming Languages
Moz
Search Marketing
Bitbucket
Source Code Management
Vimeo
Video Players

Media & News

Rhythm Pharmaceuticals Announces Presentation of Four Datasets at ObesityWeek® 2025
– Phase 3 TRANSCEND trial data showed setmelanotide achieved significant BMI reductions in patients with acquired hypothalamic obesity on concomitant treatment with GLP-1 therapy – – Analysis of data from Phase 3 TRANSCEND trial show clinically meaningful changes in cardiometabolic parameters in patients with acquired hypothalamic obesity treated with setmelanotide for 52 weeks – BOSTON, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that Rhythm and its partners delivered four Rhythm data presentations at ObesityWeek® 2025, held last week in Atlanta, GA. “Acquired hypothalamic obesity is a severe and complex disease that profoundly impacts the lives of patients and families, affecting not only body weight and hunger, but also causing severe implications for daily functioning,” said Christian Roth, M.D.
Nov 10, 2025 | www.globenewswire.com
Rythm Pharmaceuticals' (RYTM) Chief Technical Officer Sells 9,748 Shares for $1.1 Million
Rythm Pharmaceuticals' Chief Technical Officer, Joseph Shulman, recently exercised and sold some stock options. Shulman still held 8,509 shares directly after the trade.
Nov 08, 2025 | www.fool.com
Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity
-- FDA sets updated PDUFA goal date of March 20, 2026 – -- Company to hold conference today at 8:00 a.m. -- BOSTON, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that the U.S. Food and Drug Administration (FDA) has extended by three months the review period for the supplemental New Drug Application (sNDA) for IMCIVREE® (setmelanotide) for the treatment of acquired hypothalamic obesity.
Nov 07, 2025 | www.globenewswire.com
AlphaQuest LLC Decreases Stake in Rhythm Pharmaceuticals, Inc. $RYTM
AlphaQuest LLC lowered its stake in Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) by 77.8% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,470 shares of the company's stock after selling 5,137 shares during the period. AlphaQuest LLC's holdings
Nov 06, 2025 | www.defenseworld.net
Rhythm Pharmaceuticals Announces Public Reimbursement for IMCIVREE® (setmelanotide) in Canada in Five Provinces and Under the Federal Non-Insured Health Benefits Program
BOSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it has entered into Product Listing Agreements in the provinces of Ontario, Alberta, British Columbia, Saskatchewan, Nova Scotia and with the Federal Non-Insured Health Benefits (NIHB) Program for the public reimbursement of IMCIVREE for weight management in eligible adult and pediatric patients aged 6 years and older with clinically or genetically confirmed Bardet-Biedl syndrome (BBS) and obesity. “These listing agreements for IMCIVREE mark a significant milestone for individuals living with obesity due to Bardet-Biedl syndrome,” said Prof.
Nov 05, 2025 | www.globenewswire.com
Rhythm Pharmaceuticals, Inc. (RYTM) Q3 2025 Earnings Call Transcript
Rhythm Pharmaceuticals, Inc. ( RYTM ) Q3 2025 Earnings Call November 4, 2025 8:00 AM EST Company Participants David Connolly - Head of Investor Relations & Corporate Communications David Meeker - Chairman, President & CEO Jennifer Chien - Executive VP & Head of North America Yann Mazabraud - Executive VP & Head of International Hunter Smith - CFO & Treasurer Conference Call Participants Michael Ulz - Morgan Stanley, Research Division Philip Nadeau - TD Cowen, Research Division Derek Archila - Wells Fargo Securities, LLC, Research Division Angela Qian Faisal Khurshid - Leerink Partners LLC, Research Division Erik Wong Julian Pino Evan Wang Georgia Ban Raghuram Selvaraju - H.C. Wainwright & Co, LLC, Research Division Jonathan Wolleben - Citizens JMP Securities, LLC, Research Division Presentation Operator " David Connolly Head of Investor Relations & Corporate Communications " David Meeker Chairman, President & CEO " Jennifer Chien Executive VP & Head of North America " Yann Mazabraud Executive VP & Head of International " Hunter Smith CFO & Treasurer " Michael Ulz Morgan Stanley, Research Division " Morgan Stanley, Research Division Philip Nadeau TD Cowen, Research Division " TD Cowen, Research Division Derek Archila Wells Fargo Securities, LLC, Research Division " Wells Fargo Securities, LLC, Research Division Angela Qian " Canaccord Genuity, Research Division Faisal Khurshid Leerink Partners LLC, Research Division " Leerink Partners LLC, Research Division Erik Wong " Goldman Sachs, Research Division Julian Pino " Stifel, Nicolaus & Company, Incorporated, Research Division Evan Wang " Guggenheim Securities, LLC, Research Division Georgia Ban " Jefferies LLC, Research Division Raghuram Selvaraju H.C.
Nov 04, 2025 | seekingalpha.com
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q3 Loss, Tops Revenue Estimates
Rhythm Pharmaceuticals, Inc. (RYTM) came out with a quarterly loss of $0.82 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to a loss of $0.73 per share a year ago.
Nov 04, 2025 | www.zacks.com

Rhythm's Email Address Formats

Rhythm uses at least 1 format(s):

Rhythm Email Formats	Example	Percentage
First.Last@rhythmagency.com	John.Doe@rhythmagency.com	47%
Last@rhythmagency.com	Doe@rhythmagency.com	5%
First@rhythmagency.com	John@rhythmagency.com	1%
First.Last@rhythmagency.com	John.Doe@rhythmagency.com	47%

Frequently Asked Questions

Where is Rhythm's headquarters located?

Rhythm's main headquarters is located at 9860 Irvine Center Dr, Irvine, CA 92618, US. The company has employees across 6 continents, including North AmericaAsiaAfrica.

What is Rhythm's stock symbol?

Rhythm is a publicly traded company; the company's stock symbol is RYTM.

What is Rhythm's official website and social media links?

Rhythm's official website is rhythmagency.com and has social profiles on LinkedIn.

What is Rhythm's SIC code NAICS code?

Rhythm's SIC code is 8742 - Management Consulting Services NAICS code is 541613 - Marketing Consulting Services.

How many employees does Rhythm have currently?

As of October 2025, Rhythm has approximately 114 employees across 6 continents, including North AmericaAsiaAfrica. Key team members include Chief Executive Officer: C. C.Chief Executive Officer: D. G.Ceoco-Founder: M. C.. Explore Rhythm's employee directory with LeadIQ.

What industry does Rhythm belong to?

Rhythm operates in the Advertising Services industry.

What technology does Rhythm use?

Rhythm's tech stack includes Adobe TargetLinkedin Insight TagCloudflareShopifyGraphQLMozBitbucketVimeo.

What is Rhythm's email format?

Rhythm's email format typically follows the pattern of First.Last@rhythmagency.com. Find more Rhythm email formats with LeadIQ.

When was Rhythm founded?

Rhythm was founded in 1996.

Rhythm

Q: What is Rhythm's official website and social media links?

Rhythm's official website is rhythmagency.com. Rhythm has social profiles on LinkedIn.

Q: How many employees does Rhythm have currently?

Rhythm has approximately 114 employees.

Q: What technology does Rhythm use?

Rhythm's tech stack includes Netlify, Google Analytics 4, Basecamp, Omniture, Brandwatch.

Advertising ServicesUnited States51-200 Employees

Rhythm is a digital agency that creates effective brand experiences that achieve results through integrated digital marketing solutions layered on a solid infrastructure.